trial

Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study

NCTId NCT04605393
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 36 (actual)
Sponsored by King's College London
Primary completion 2023-07-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
36 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2021-01-01
Primary completion
2023-07-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
CannabidiolDelta-9-THC

Sponsors

King's College LondonLead Sponsor

Investigators

1
Gill DaleStudy Chair

Sites

1 total
London, United Kingdom

Facts & assertions

4 sourced
Enrollment
36
Phase
NA
Primary Completion Date
2023-07-07
Status
COMPLETED
relationships
The graph out of here
drug
Cannabidiol
drug
Delta-9-THC
drug
lead_sponsor
King's College London
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cannabis Use
indication
investigator
Gill Dale
person